Antabio Sas
Antabio is a privately-held clinical-stage biopharmaceutical company dedicated to developing novel and highly differentiated antibacterial treatments for drug-resistant infections caused by WHO and CDC critical priority pathogens. The company focuses on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases. With an international team of experts and a strong track record of attracting non-dilutive funding, Antabio aims to address urgent unmet medical needs in the antibacterial space.
Industries
Nr. of Employees
small (1-50)
Products
Intravenous carbapenem plus serine β-lactamase inhibitor combination for severe hospital Gram-negative infections
A β-lactam/β-lactamase inhibitor combination developed to restore carbapenem activity against carbapenem-resistant Enterobacterales, carbapenem-resistant Acinetobacter baumannii and other priority Gram-negative pathogens; developed through clinical trials for hospital-acquired infections including nosocomial pneumonia.
Inhaled elastase inhibitor for Pseudomonas aeruginosa respiratory infections
Nebuliser-administered inhaled small-molecule inhibitor targeting Pseudomonas elastase to reduce virulence and support treatment of chronic respiratory infections such as cystic fibrosis, bronchiectasis and COPD.
Metallo-β-lactamase inhibitor to restore carbapenem activity against NDM-producing strains
A small-molecule metallo-β-lactamase inhibitor developed to potentiate carbapenem antibiotics against NDM-positive Enterobacterales and similar resistant pathogens (preclinical and publication-supported program).
Intravenous carbapenem plus serine β-lactamase inhibitor combination for severe hospital Gram-negative infections
A β-lactam/β-lactamase inhibitor combination developed to restore carbapenem activity against carbapenem-resistant Enterobacterales, carbapenem-resistant Acinetobacter baumannii and other priority Gram-negative pathogens; developed through clinical trials for hospital-acquired infections including nosocomial pneumonia.
Inhaled elastase inhibitor for Pseudomonas aeruginosa respiratory infections
Nebuliser-administered inhaled small-molecule inhibitor targeting Pseudomonas elastase to reduce virulence and support treatment of chronic respiratory infections such as cystic fibrosis, bronchiectasis and COPD.
Metallo-β-lactamase inhibitor to restore carbapenem activity against NDM-producing strains
A small-molecule metallo-β-lactamase inhibitor developed to potentiate carbapenem antibiotics against NDM-positive Enterobacterales and similar resistant pathogens (preclinical and publication-supported program).
Expertise Areas
- Antibacterial drug discovery and development
- β-lactamase inhibitor discovery (serine and metallo classes)
- Clinical development of anti-infectives (early-phase)
- Inhalation therapeutics and nebulised delivery
Key Technologies
- Serine β-lactamase inhibition
- Metallo β-lactamase inhibition
- Combination β-lactam + β-lactamase inhibitor therapy
- Inhalation/nebuliser drug delivery